Karyopharm Therapeutics (KPTI) Free Cash Flow (2012 - 2025)

Karyopharm Therapeutics has reported Free Cash Flow for 14 years, with the latest figure at -$11.8 million in Q4 2025.

• For the quarter ending Q4 2025, Free Cash Flow rose 54.08% year-over-year to -$11.8 million; the trailing twelve-month figure through Dec 2025 stood at -$75.4 million (up 40.95% YoY), and the FY2025 full-year result was -$75.4 million, up 40.95% from the prior year.
• Free Cash Flow for Q4 2025 stood at -$11.8 million, down from -$5.9 million in the prior quarter.
• The five-year high for Free Cash Flow was $25.3 million in Q4 2021, with the low at -$59.3 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$27.6 million across 5 years, with a median of -$26.3 million in 2022.
• Annual changes were most pronounced in 2021 — Free Cash Flow jumped 182.16% — and 2022, when it sank 206.23%.
• Karyopharm Therapeutics' Free Cash Flow stood at $25.3 million in 2021, then slumped by 206.23% to -$26.8 million in 2022, then soared by 30.76% to -$18.6 million in 2023, then sank by 38.59% to -$25.8 million in 2024, then soared by 54.08% to -$11.8 million in 2025.
• The last three Free Cash Flow figures came in at -$11.8 million (Q4 2025), -$5.9 million (Q3 2025), and -$18.7 million (Q2 2025), per Business Quant data.